MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more
MoonLake Immunotherapeutics (MLTX) - Net Assets
Latest net assets as of December 2025: $304.48 Million USD
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has net assets worth $304.48 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($424.43 Million) and total liabilities ($119.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $304.48 Million |
| % of Total Assets | 71.74% |
| Annual Growth Rate | 22.04% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 304.62 |
MoonLake Immunotherapeutics - Net Assets Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual net assets of MoonLake Immunotherapeutics from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $304.48 Million | -32.84% |
| 2024-12-31 | $453.39 Million | -11.70% |
| 2023-12-31 | $513.49 Million | +646.71% |
| 2022-12-31 | $68.77 Million | +690.53% |
| 2021-12-31 | $-11.65 Million | -110.35% |
| 2020-12-31 | $112.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MoonLake Immunotherapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46039438400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $604.00K | 0.20% |
| Other Components | $766.78 Million | 251.83% |
| Total Equity | $304.48 Million | 100.00% |
MoonLake Immunotherapeutics Competitors by Market Cap
The table below lists competitors of MoonLake Immunotherapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen SEG Co Ltd
SHE:000058
|
$595.06 Million |
|
Vanchip (Tianjin) Technology Co. Ltd. A
SHG:688153
|
$595.20 Million |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
$595.54 Million |
|
Emei Shan Tourism Co Ltd
SHE:000888
|
$595.56 Million |
|
Borusan Yatirim ve Pazarlama AS
IS:BRYAT
|
$594.49 Million |
|
Bank Islam Malaysia Bhd
KLSE:5258
|
$594.30 Million |
|
Kuros Biosciences AG
PINK:CSBTF
|
$594.01 Million |
|
Elopak AS
OL:ELO
|
$593.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MoonLake Immunotherapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 446,825,002 to 304,481,000, a change of -142,344,002 (-31.9%).
- Net loss of 227,318,000 reduced equity.
- New share issuances of 72,395,000 increased equity.
- Other comprehensive income decreased equity by 4,392,769.
- Other factors increased equity by 16,971,767.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-227.32 Million | -74.66% |
| Share Issuances | $72.39 Million | +23.78% |
| Other Comprehensive Income | $-4.39 Million | -1.44% |
| Other Changes | $16.97 Million | +5.57% |
| Total Change | $- | -31.86% |
Book Value vs Market Value Analysis
This analysis compares MoonLake Immunotherapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.21x to 3.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $7.60 | $16.77 | x |
| 2021-12-31 | $-0.32 | $16.77 | x |
| 2022-12-31 | $1.67 | $16.77 | x |
| 2023-12-31 | $10.09 | $16.77 | x |
| 2024-12-31 | $7.11 | $16.77 | x |
| 2025-12-31 | $4.72 | $16.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MoonLake Immunotherapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -74.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.39x
- Recent ROE (-74.66%) is below the historical average (-40.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -0.08% | 0.00% | 0.00x | 1.04x | $-11.34 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.38 Million |
| 2022 | -131.92% | 0.00% | 0.00x | 1.57x | $-69.40 Million |
| 2023 | -7.26% | 0.00% | 0.00x | 1.06x | $-85.57 Million |
| 2024 | -26.62% | 0.00% | 0.00x | 1.07x | $-163.62 Million |
| 2025 | -74.66% | 0.00% | 0.00x | 1.39x | $-257.77 Million |
Industry Comparison
This section compares MoonLake Immunotherapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $304.48 Million | -0.08% | 0.39x | $594.94 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |